No Data
No Data
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
Zhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand
ZHAOKE OPHTH-B (06622.HK): A distribution agreement has been established with AFT PHARMACEUTICALS for the commercialization of BRIMOCHOL PF in Australia and New Zealand.
On January 13, Gelonghui reported that ZHAOKE OPHTH-B (06622.HK) announced that the company has signed a distribution and supply agreement with AFT Pharmaceuticals Limited ("AFT", a leading manufacturer and distributor of healthcare products based in New Zealand) for BRIMOCHOL PF ("the product"). BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia. The company has discussed BRIMOCHOL PF with Tenpoint Therapeutics.
Express News | Zhaoke Ophthalmology Ltd - Entering Into Distribution- Agreement With AFT Pharmaceuticals
ZHAOKE OPHTH-B (6622.HK): The registration application for NVK002 has been formally accepted, further enhancing growth certainty.
Nowadays, the issue of myopia in children is becoming increasingly serious, and how to prevent and delay the development of myopia in children has become a focus of widespread attention among parents. As a result, various treatment methods have emerged in the market, and related discussions have become more intense. From traditional glasses to modern orthokeratology lenses and defocus lenses, as well as drug treatments, parents are urgently seeking suitable solutions for their children, hoping to find the safest and most effective way to delay myopia as soon as possible. Recently, Zhaoke Ophthalmology announced the simple new drug application for NVK002 (0.01% low-dose atropine), a medication used to control the progression of myopia in children, which has been officially accepted by the National Medical Products Administration. This means that
Selected Announcements | Alibaba's buyback plan still has a remaining amount of 20.7 billion USD; GTJA plans to conduct a stock swap to absorb and merge HAITONG SEC and will send a proposal to the meeting for fundraising support.
In 2024, Qinhuangdao Port's total throughput reached 0.414 billion tons, a year-on-year increase of 5.66%; ZHAOKE OPHTH-B: The National Medical Products Administration accepted the simplified new drug application for NVK002, used to treat worsening myopia in children.